INTRODUCTION
The competencies required in the domain to implement processes for the prevention of HIV transmission and infection.
| 3.1 | Implement PrEP in the PIMART environment. |
| 3.2 | Conduct pregnancy screening and recommend contraception in the PIMART context. |
| 3.3 | Implement pre-conception management for HIV positive couples. |
DOMAIN 3: IMPLEMENT PROCESSES FOR THE PREVENTION OF HIV TRANSMISSION AND INFECTION VIA PrEP, SAFER CONCEPTION AND CONTRACEPTION, AND PREVENTION OF MOTHER TO CHILD TRANSMISSION
|
COMPETENCIES
|
BEHAVIOURAL STATEMENTS
|
| 3.1 | Implement PrEP in the PIMART environment |
|
| 3.1.1 | Interpreting and applying the steps in the treatment process. |
Range: screening, initiation, follow-up, maintenance, adherence support, FAQs and stopping PrEP.
| 3.1.2 | Implementing the PEP to PrEP transition, and the prevention continuum and failure referral. |
| 3.1.3 | Describing PrEP administration methods and components. |
| 3.1.4 | Describing PrEP regimen options and nomenclature. |
| 3.1.5 | Analysing the pharmacology, dosing, safety, toxicity monitoring and side effects of medicines recommended by NDoH for PrEP. |
| 3.1.6 | Describing PrEP indications, contra-indications, and practical application in the pharmacy context. |
|
| 3.2 | Conduct pregnancy screening and recommend contraception in the PIMART context |
|
| 3.2.1 | Carrying out a basic fertility intention screen and referring patients who wish to conceive. |
| 3.2.2 | Demonstrating an understanding of processing pregnancy test results. |
Range: positive, STI and HIV screening, negative with pregnancy intent, negative without pregnancy intent.
| 3.2.3 | Listing and describing the types of available contraceptives. |
Range: classification, dosing, and efficacy.
| 3.2.4 | Describing indications for contraception. |
Range: women who may wish to conceive in the future, and women who do not wish to conceive at all, contraception eligibility, and general use in South Africa.
| 3.2.5 | Describing the link between contraception and HIV. |
Range: injectable link to incidence, HIV and contraception choices and safety, contraception impact on risk.
|
| 3.3 | Implement pre-conception management for HIV positive couples |
|
| 3.3.1 | Describing key aspects to consider ensuring conception occurs safely, and knowledge of how to minimise the risks of partner acquiring HIV. |
| 3.3.2 | Describing methods used to ensure safe conception. |
Range: ART, PrEP, VMMC, STI treatment, timed intercourse without the use of a condom and self-insemination.
| 3.3.3 | Demonstrate application of couple counselling skills when working with discordant couples. |
|
| 3.4 | Demonstrate knowledge of PMTCT and the rationale for PMTCT programmes |
|
| 3.4.1 | Demonstrating knowledge of the MTCT risk and risk factors in South Africa. |
| 3.4.2 | Demonstrating knowledge of the ideal treatment pathway for PMTCT. |
| 3.4.3 | Demonstrating knowledge of the safety and efficacy of various pharmacological therapies in PMTCT. |
| 3.4.4 | Demonstrate knowledge of the factors that improve and impede adherence and retention in PMTCT interventions. |
| 3.4.5 | Demonstrating knowledge of appropriate viral load monitoring and responses in PMTCT. |
|
